Efficacy & Safety of Histamine Human Immunoglobulin in the Treatment of

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06077773` - Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria	Phase 2
Completed	`NCT04538794` - A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria	Phase 1
Completed	`NCT01803763` - Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients	Phase 2/Phase 3
Recruiting	`NCT05298215` - A Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of UB-221 IV Infusion as an add-on Therapy in Patients With Chronic Spontaneous Urticaria	Phase 2
Terminated	`NCT04612725` - A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)	Phase 2
Terminated	`NCT05528861` - A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria	Phase 2
Completed	`NCT04109313` - An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU	Phase 2
Completed	`NCT03580356` - A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.	Phase 3
Completed	`NCT03580369` - A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines	Phase 3
Completed	`NCT05030311` - A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines	Phase 3
Recruiting	`NCT06162728` - Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)	Phase 1/Phase 2
Completed	`NCT05107115` - Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine	Phase 2
Recruiting	`NCT06042478` - A Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo and With Omalizumab as Active Control in CSU Adult Patients.	Phase 3
Terminated	`NCT04159701` - A Study of LY3454738 in Adults With Chronic Spontaneous Urticaria	Phase 2
Completed	`NCT03749135` - Dupilumab in Chronic Spontaneous Urticaria	Phase 2
Not yet recruiting	`NCT06396026` - A Study of Efficacy and Safety of TLL-018 in CSU Participants	Phase 3
Completed	`NCT02649218` - A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients	Phase 2
Active, not recruiting	`NCT05368285` - A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria	Phase 2
Completed	`NCT05373355` - Safety and Efficacy of TLL018 in Patients With Chronic Spontaneous Urticaria.	Phase 1
Not yet recruiting	`NCT06365879` - To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria	Phase 3

NCT number	NCT06250400
Study type	Interventional
Source	Hangzhou Grand Biologic Pharmaceutical, Inc.
Contact	Kai Guan
Phone	010-69156874
Email	dr_guankai@126.com
Status	Not yet recruiting
Phase	Phase 4
Start date	March 31, 2024
Completion date	December 31, 2025

Efficacy and Safety of Histamine Human Immunoglobulin in the Treatment of Chronic Spontaneous Urticaria (CSU)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms